尚健生物

Media Report

28 2024-06

Major Milestone! Enlonstobart Injection (Enshuxin®) Approved For Listing Domestically!

On June 28, 2024, Enlonstobart for Injection (Tra......
15 2024-06

Sumgen Biotech's Innovative injectable antibody SG301 Has Completed the First Dose for the First Patient In Phase Ⅲ Clinical Trial

Hangzhou, China - June 14, 2024 - Hangzhou Sumgen ......
27 2023-12

Sumgen Biotech's Novel ADC Candidate SG2918 For Injection Has Commenced Firs-In-Human Study

On December 27th, 2023, Hangzhou Sumgen Biotech C......
20 2023-11

Sumgen Biotech's Innovative subcutaneous injectable antibody SG301 SC Has Commenced First-In-Human Study

On November 20th, 2023, Hangzhou Sumgen Biotech ......
20 2023-10

Sumgen Biotech's First-In-Class ADC SG2918 Has Received IND Clearance From The National Medical Products Administration

On October 20th, 2023, Hangzhou Sumgen Biotech Co......
28 2023-09

Sumgen Biotech's innovative drug injection SG1827 completed the first subject dosing in Phase I clinical trial

On September 28th, Hangzhou Shangjian Biotechnol......
21 2023-08

Sumgen Biotech's Class 1 New Drug SG1827 for Injection Has Received Clinical Trial Approval from the National Medical Products Administration

On August 21, 2023, Hangzhou Sumgen Biotech Co., Ltd. (hereinafter referred to as \"Sumgen Biotech\") announced that it has received approval from the National Medical Products Administration (NM
31 2023-07

Clinical Trial Application of Sumgen Biotech's First-in-class Same-Target ADC Drug SG2918 Accepted by NMPA

On July 31, 2023, Hangzhou Sumgen Biotech Co., Ltd. (hereinafter referred to as \"Sumgen Biotech\") announced that the clinical trial application for its independently developed first Class 1 in

prev 1 2 3 4 next

<1/4>

Copyright Rm. 301, F3, Building C, Block 2, No. 688, Bin'an Road, Changhe Zhejiang ICP Filing No. 18039044